ERBB2 and breast cancer: The therapeutic scenario of HER2-positive BC patients diagnosed with BM has radically changed over the last few decades with the introduction of several novel HER2-targeted agents with relevant intracranial activity alongside with improvements in locoregional treatment modalities [18].